Cold is an infectious disease that affects the respiratory system. The common symptoms for cold include sneezing, sore throat, a stuffy nose, and coughing. Cold remedies are used to treat cold in immunosuppressed individuals. The composition of many cold medicines are same and therefore taking too much of certain medication can lead to drug resistance or serious injury.

Rise in geriatric population, demand for effective combination products, and switch from Rx to OTC category drive the market. However, competition faced by international players due to drugs from local manufacturers and natural remedies restrain the market growth. Favorable regulations and opportunities in the emerging economies of Asia-Pacific and LAMEA due to availability of large patient pools provide growth prospects for the market.

The report segments the global cold remedies market based on drug type, dosage type, end user, and region. Based on drug type, it is divided into antihistamines, expectorants, bronchodilators, decongestants, antibiotics, and others. Based on dosage type, it is classified into oral syrups, tablets/pills, nasal drops, lozenges, and others.

By distribution channel, it is categorized into hospital pharmacies, retail pharmacies, drug stores, supermarkets/hypermarkets, and e-commerce/online pharmacies. By geography, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Key players operating in the market include Reckitt Benckiser Group plc, Johnson & Johnson, GlaxoSmithKline plc, Novartis AG, Bayer AG, AstraZeneca plc, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Prestige Brands Holdings, Inc., and Procter & Gamble Co.

Key Benefits

• The study provides an in-depth analysis of the global market with current trends and future estimations to elucidate the imminent investment pockets.
• The report provides a quantitative analysis from 2016 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
• Competitive intelligence highlights the business practices followed by leading players across various regions.
• Comprehensive analysis of all geographic regions are provided that helps determine the prevailing opportunities in these regions.
• Key market players within the market are profiled in the report and their strategies are analyzed thoroughly, which elucidates the competitive outlook of the global market.
• Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

Cold Remedies Market Key Segments:

By Drug Type

• Antihistamines
• Expectorants
• Bronchodilators
• Decongestants
• Antibiotics
• Others

By Dosage Type

• Oral Syrups
• Tablets/Pills
• Nasal Drops
• Lozenges
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Supermarkets/Hypermarkets
• e-Commerce/Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 COLD REMEDIES MARKET, BY DRUG TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ANTIHISTAMINES

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. EXPECTORANTS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. BRONCHODILATORS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. DECONGESTANTS

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. ANTIBIOTICS

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. OTHERS

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

CHAPTER 5 COLD REMEDIES MARKET, BY DOSAGE TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ORAL SYRUPS

5.2.1. Market size and forecast

5.3. TABLETS/PILLS

5.3.1. Market size and forecast

5.4. NASAL DROPS

5.4.1. Market size and forecast

5.5. LOZENGES

5.5.1. Market size and forecast

5.6. OTHERS

5.6.1. Market size and forecast

CHAPTER 6 COLD REMEDIES MARKET, BY DISTRIBUTION CHANNEL

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. HOSPITAL PHARMACIES

6.2.1. Market size and forecast

6.3. RETAIL PHARMACIES

6.3.1. Market size and forecast

6.4. DRUG STORES

6.4.1. Market size and forecast

6.5. SUPERMARKETS/HYPERMARKETS

6.5.1. Market size and forecast

6.6. E-COMMERCE/ONLINE PHARMACIES

6.6.1. Market size and forecast

CHAPTER 7 COLD REMEDIES MARKET, BY REGION

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.2.4. North America Cold Remedies Market by Drug Type
7.2.5. North America Cold Remedies Market by Dosage Type
7.2.6. North America Cold Remedies Market by Distribution Channel

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.3.4. Europe Cold Remedies Market by Drug Type
7.3.5. Europe Cold Remedies Market by Dosage Type
7.3.6. Europe Cold Remedies Market by Distribution Channel

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. South Korea market size and forecast
7.4.3.6. Rest of Asia-Pacific market size and forecast

7.4.4. Asia-Pacific Cold Remedies Market by Drug Type
7.4.5. Asia-Pacific Cold Remedies Market by Dosage Type
7.4.6. Asia-Pacific Cold Remedies Market by Distribution Channel

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Saudi Arabia market size and forecast
7.5.3.3. South Africa market size and forecast
7.5.3.4. Rest of LAMEA market size and forecast

7.5.4. LAMEA Cold Remedies Market by Drug Type
7.5.5. LAMEA Cold Remedies Market by Dosage Type
7.5.6. LAMEA Cold Remedies Market by Distribution Channel

CHAPTER 8 COMPANY PROFILES

8.1. RECKITT BENCKISER GROUP PLC

8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments

8.2. JOHNSON & JOHNSON

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. GLAXOSMITHKLINE PLC.

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. NOVARTIS AG

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. BAYER AG

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.6. ASTRAZENECA PLC

8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments

8.7. SUN PHARMACEUTICAL INDUSTRIES LTD.

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. PFIZER INC.

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.9. PRESTIGE BRANDS HOLDINGS, INC.

8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments

8.10. PROCTER & GAMBLE CO.

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments